NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

GenSight Biologics S.A (PA: SIGHT)

 
SIGHT Technical Analysis
5
As on 21st Nov 2024 SIGHT STOCK Price closed @ 0.32 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.51 & Strong Sell for SHORT-TERM with Stoploss of 0.61 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

SIGHTSTOCK Price

Open 0.31 Change Price %
High 0.32 1 Day 0.01 3.23
Low 0.30 1 Week 0.02 6.67
Close 0.32 1 Month -0.05 -13.51
Volume 175721 1 Year -0.48 -60.00
52 Week High 0.90 | 52 Week Low 0.28
 
PA France Most Active Stocks
ALNEV 0.00 %
FTI 5.91 -1.66%
VIEDS 0.72 4.35%
ALVER 0.00 %
ATO 0.16 -15.79%
ALMAS 0.01 0.00%
CGG 0.69 -2.82%
ALDRV 0.00 %
ELIOR 2.75 -11.86%
ALHYG 0.01 0.00%
 
PA France Top Gainers Stocks
MLIML 0.36 20.00%
HDP 1.43 14.40%
HDP 1.43 14.40%
ALTBG 0.34 13.33%
ALGLD 5.40 10.66%
ALKLK 0.54 10.20%
MLPHO 0.12 9.09%
ALTHE 0.37 8.82%
ALEMV 0.87 8.75%
PARRO 2.52 8.62%
 
PA France Top Losers Stocks
AKOM 4.06 -37.05%
AKOM 4.06 -37.05%
FPN 0.02 -33.33%
ALDOL 2.30 -19.58%
CNV 0.80 -19.19%
ATO 0.16 -15.79%
ATO 0.16 -15.79%
ATO 0.16 -15.79%
ATO 0.16 -15.79%
ATO 0.16 -15.79%
 
 
SIGHT
Daily Charts
SIGHT
Intraday Charts
Whats New @
Bazaartrend
SIGHT
Free Analysis
 
SIGHT Important Levels Intraday
RESISTANCE0.36
RESISTANCE0.35
RESISTANCE0.34
RESISTANCE0.33
SUPPORT0.31
SUPPORT0.30
SUPPORT0.29
SUPPORT0.28
 
SIGHT Forecast November 2024
4th UP Forecast1.01
3rd UP Forecast0.79
2nd UP Forecast0.65
1st UP Forecast0.52
1st DOWN Forecast0.12
2nd DOWN Forecast-0.01
3rd DOWN Forecast-0.15
4th DOWN Forecast-0.37
 
SIGHT Weekly Forecast
4th UP Forecast0.44
3rd UP Forecast0.40
2nd UP Forecast0.38
1st UP Forecast0.35
1st DOWN Forecast0.29
2nd DOWN Forecast0.26
3rd DOWN Forecast0.24
4th DOWN Forecast0.20
 
SIGHT Forecast2024
4th UP Forecast1.55
3rd UP Forecast1.16
2nd UP Forecast0.91
1st UP Forecast0.67
1st DOWN Forecast-0.03
2nd DOWN Forecast-0.27
3rd DOWN Forecast-0.52
4th DOWN Forecast-0.91
 
 
SIGHT Other Details
Segment EQ
Market Capital 321960896.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
SIGHT Address
SIGHT
 
SIGHT Latest News
 
Your Comments and Response on GenSight Biologics S.A
 
SIGHT Business Profile
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase III clinical trial for the treatment of retinitis pigmentosa, as well as in Phase I/II clinical trial to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France. Address: 74, rue du Faubourg Saint-Antoine, Paris, France, 75012
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service